Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis

BACKGROUND: Hepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world’s population. Some studies have shown that adding Sofosbuvir (SOF), an HCV polymerase inhibitor to the conventional therapy of Pegylated-interferon (PegIFN) plus Ribavirin...

詳細記述

保存先:
書誌詳細
出版年:Daru
主要な著者: Dolatimehr, Fardin, Karimi-Sari, Hamidreza, Rezaee-Zavareh, Mohammad Saeid, Alavian, Seyed Moayed, Behnava, Bita, Gholami-Fesharaki, Mohammad, Sharafi, Heidar
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2017
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5397824/
https://ncbi.nlm.nih.gov/pubmed/28427463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40199-017-0177-x
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料